Potential role of vasomotor effects of fibrinogen in bradykinin-induced angioedema

Journal of Allergy and Clinical Immunology

Volumn 121, Issue 4, 2008, Pages

  Bas, Murat ^a   Kirchhartz, Nadine ^b   Hochfeld, Jessica ^b   Tüllmann, Cornelia ^b   Kumpf, Stephanie ^b   Suvorava, Tatsiana ^b   Oppermann, Marc ^b   Hafner, Dieter ^b   Bier, Henning ^a   Hoffmann, Thomas K ^c   Balz, Vera ^c   Kojda, Georg ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Institut fur Pharmakologie und Klinische Pharmakologie   (Germany)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

acute phase protein; Angioedema; angiotensin converting enzyme inhibitor; bradykinin; fibrinogen

Indexed keywords

ABCIXIMAB; ADRENALIN; BRADYKININ; CLEMASTINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; GLIBENCLAMIDE; N(G) NITROARGININE METHYL ESTER; PHOSPHOPROTEIN; PREDNISOLONE;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; INTERNAL MAMMARY ARTERY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; VASODILATATION;

EID: 41549158309     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.01.071     Document Type: Article

References (31)

1. Bas M., Adams V., Suvorava T., Niehues T., Hoffmann T.K., and Kojda G. Non-allergic angioedema. Role of bradykinin. Allergy 62 (2007) 842-856
2. Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.L., Kober L., Maggioni A.P., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
3. Agostoni A., and Cicardi M. Drug-induced angioedema without urticaria. Drug Saf 24 (2001) 599-606
4. Messerli F.H., and Nussberger J. Vasopeptidase inhibition and angio-oedema. Lancet 356 (2000) 608-609
5. Bas M., Kojda G., Bier H., and Hoffmann T.K. Durch ACE-Hemmer induziertes Angioödem des Kopf-Hals-Bereichs. Eine Frage der Zeit?. HNO 52 (2004) 886-890
6. Nussberger J., Cugno M., Amstutz C., Cicardi M., Pellacani A., and Agostoni A. Plasma bradykinin in angio-oedema. Lancet 351 (1998) 1693-1697
7. Nussberger J., Cugno M., and Cicardi M. Bradykinin-mediated angioedema. N Engl J Med 347 (2002) 621-622
8. Han E.D., MacFarlane R.C., Mulligan A.N., Scafidi J., and Davis III A.E. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 109 (2002) 1057-1063
9. Adam A., Cugno M., Molinaro G., Perez M., Lepage Y., and Agostoni A. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 359 (2002) 2088-2089
10. Blais Jr. C., Rouleau J.L., Brown N.J., Lepage Y., Spence D., Munoz C., et al. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 43 (1999) 293-302
11. Lefebvre J., Murphey L.J., Hartert T.V., Jiao S.R., Simmons W.H., and Brown N.J. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension 39 (2002) 460-464
12. Vleeming W., van Amsterdam J.G., Stricker B.H., and De Wildt D.J. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf 18 (1998) 171-188
13. Gainer J.V., Nadeau J.H., Ryder D., and Brown N.J. Increased sensitivity to bradykinin among African Americans. J Allergy Clin Immunol 98 (1996) 283-287
14. McDowell S.E., Coleman J.J., and Ferner R.E. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 332 (2006) 1177-1181
15. Gibbs C.R., Lip G.Y., and Beevers D.G. Angioedema due to ACE inhibitors: increased risk in patients of African origin. Br J Clin Pharmacol 48 (1999) 861-865
16. Ajayi A.A., and Adigun A.Q. Angioedema and cough in Nigerian patients receiving ACE inhibitors. Br J Clin Pharmacol 50 (2000) 81-82
17. Bas M., Hoffmann T.K., Bier H., and Kojda G. Increased C-reactive protein in ACE-inhibitor-induced angioedema. Br J Clin Pharmacol 59 (2005) 233-238
18. Herrick S., Blanc-Brude O., Gray A., and Laurent G. Fibrinogen. Int J Biochem Cell Biol 31 (1999) 741-746
19. Hicks R.C., Golledge J., Mir-Hasseine R., and Powell J.T. Vasoactive effects of fibrinogen on saphenous vein. Nature 379 (1996) 818-820
20. Lominadze D., Tsakadze N., Sen U., Falcone J.C., and D'Souza S.E. Fibrinogen and fragment D-induced vascular constriction. Am J Physiol Heart Circ Physiol 288 (2005) H1257-H1264
21. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
22. Kojda G., Laursen J.B., Ramasamy S., Kent J.D., Kurz S., Burchfield J., et al. Protein expression, vascular reactivity and soluble guanylate cyclase activity in mice lacking the endothelial nitric oxide synthase: contributions of NOS isoforms to blood pressure and heart rate control. Cardiovasc Res 42 (1999) 206-213
23. Smolenski A., Burkhardt A.M., Eigenthaler M., Butt E., Gambaryan S., Lohmann S.M., et al. Functional analysis of cGMP-dependent protein kinases I and II as mediators of NO/cGMP effects. Naunyn Schmiedebergs Arch Pharmacol 358 (1998) 134-139
24. Stone G.W., Grines C.L., Cox D.A., Garcia E., Tcheng J.E., Griffin J.J., et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346 (2002) 957-966
25. Topol E.J., Byzova T.V., and Plow E.F. Platelet GPIIb-IIIa blockers. Lancet 353 (1999) 227-231
26. Tam S.H., Sassoli P.M., Jordan R.E., and Nakada M.T. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 98 (1998) 1085-1091
27. Martinez-Lemus L.A., Crow T., Davis M.J., and Meininger G.A. alphavbeta3- and alpha5beta1-integrin blockade inhibits myogenic constriction of skeletal muscle resistance arterioles. Am J Physiol Heart Circ Physiol 289 (2005) H322-H329
28. Schror K., and Weber A.A. Comparative pharmacology of GP IIb/IIIa antagonists. J Thromb Thrombolysis 15 (2003) 71-80
29. Hecker M., Bara A.T., and Busse R. Relaxation of isolated coronary arteries by angiotensin- converting enzyme inhibitors: role of endothelium-derived kinins. J Vasc Res 30 (1993) 257-262
30. Gewaltig M.T., and Kojda G. Vasoprotection by nitric oxide: mechanisms and therapeutic potential. Cardiovasc Res 55 (2002) 250-260
31. Agostoni A., Aygören-Pürsün E., Binkley K.E., Blanch A., Bork K., Bouillet L., et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 114 suppl (2004) S51-S131